Migard (Frovatriptan)

Frovatriptan, the active ingredient in Migard, is a Triptan (5‑HT1B/1D receptor agonist) presented as an oral tablet for oral use. It is specifically indicated for the acute treatment of migraine attacks, providing rapid relief of headache and associated symptoms such as nausea, photophobia, and phonophobia in adult patients.

GNH USA supplies Migard as a licensed, GDP‑compliant international pharmaceutical supplier, delivering the product to hospitals, pharmacies and clinics worldwide with adherence to quality standards and regulatory requirements.

Frovatriptan is a triptan indicated for the acute treatment of migraine attacks. - Acute migraine attacks: provides rapid relief of headache intensity and associated symptoms. - Migraine with aura: alleviates aura‑related discomfort and reduces headache progression. - Menstrual migraine: offers effective treatment for migraine episodes linked to the menstrual cycle.

Frovatriptan may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea: mild to moderate feeling of stomach upset. - Dizziness: transient sensation of light‑headedness. - Fatigue: general tiredness or lack of energy. - Dry mouth: reduced salivation causing throat discomfort. - Chest discomfort: mild pressure or tightness in the chest. - Somnolence: increased sleepiness.

Serious or Rare Side Effects: - Coronary vasospasm: severe constriction of coronary arteries. - Myocardial infarction: heart attack due to reduced blood flow. - Serotonin syndrome: potentially life‑threatening condition with agitation, hyperthermia, and neuromuscular abnormalities. - Severe hypertension: marked increase in blood pressure. - Allergic reactions: rash, swelling, or anaphylaxis. - Hepatic dysfunction: abnormal liver enzyme elevations.

When prescribing Migard, clinicians should consider several safety precautions to minimize risk. - Cardiovascular assessment: avoid use in patients with known coronary artery disease, uncontrolled hypertension, or history of myocardial infarction. - Medication overuse: limit treatment to no more than ten days per month to prevent rebound headaches. - Drug interactions: review concomitant serotonergic medications to reduce serotonin syndrome risk. - Pregnancy and lactation: safety has not been established; use only if potential benefit justifies potential risk. - Driving and operating machinery: dizziness or somnolence may impair ability; advise caution. - Store at ambient temperature: keep below 25 °C in the original packaging, protect from moisture and direct sunlight.

Frovatriptan can interact with other medicines, and the severity of the interaction determines the management approach.

Major Interactions (Avoid): - Ergot derivatives: combined use may cause severe vasospasm and ischemia. - Monoamine oxidase inhibitors (MAOIs): increased risk of serotonin syndrome. - SSRIs, SNRIs, or other serotonergic agents: heightened potential for serotonin syndrome.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may increase frovatriptan plasma concentrations. - Strong CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): can raise drug exposure and side‑effect risk. - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce therapeutic effectiveness.